Provision of Palliative Combined Pembrolizumab-Chemotherapy in Head and Neck Cancer in England: Time for a Review of the Evidence

被引：0
作者：
Kelly, C. [1 ]
Barnett, G. [2 ]
Iqbal, M. S. [3 ]
机构：
[1] Newcastle Tyne Hosp NHS Fdn Trust, Freeman Hosp, Northern Ctr Canc Care, Newcastle Upon Tyne NE7 7DN, England
[2] Cambridge Univ Hosp NHS Fdn Trust, Hills Rd, Cambridge CB2 0QQ, England
[3] Newcastle Univ, Freeman Hosp, Newcastle Tyne Hosp NHS Fdn Trust, Northern Ctr Canc Care, Newcastle Upon Tyne NE7 7DN, England
来源：
CLINICAL ONCOLOGY | 2024年 / 36卷 / 09期
关键词：
Chemotherapy; head and neck cancer; immunotherapy; pembrolizumab; SQUAMOUS-CELL CARCINOMA; OPEN-LABEL; CETUXIMAB; RECURRENT;
D O I：
10.1016/j.clon.2024.05.007
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：534 / 536
页数：3
相关论文
共 50 条
  • [1] Potential of Pembrolizumab in Metastatic or Recurrent Head and Neck Cancer: Evidence to Date
    McCusker, Michael G.
    Orkoulas-Razis, Dennis
    Mehra, Ranee
    ONCOTARGETS AND THERAPY, 2020, 13 : 3047 - 3059
  • [2] Retrospective analysis of palliative metronomic chemotherapy in head and neck cancer
    Patil, V. M.
    Noronha, V
    Joshi, A.
    Nayak, L.
    Pande, N.
    Chandrashekharan, A.
    Dhumal, S.
    Bhattacharjee, A.
    Banavali, S.
    Prabhash, K.
    INDIAN JOURNAL OF CANCER, 2017, 54 (01) : 25 - +
  • [3] Chemotherapy and immunotherapy for recurrent and metastatic head and neck cancer: a systematic review
    Guidi, Alessandro
    Codeca, Carla
    Ferrari, Daris
    MEDICAL ONCOLOGY, 2018, 35 (03)
  • [4] The UK Divide: Does Having a Pembrolizumab- Chemotherapy Option in Head and Neck Cancer Matter? Real-world Experience of First-line Palliative Pembrolizumab Monotherapy and Pembrolizumab- Chemotherapy Combination in Scotland
    Thapa, A.
    Cowell, A.
    Peters, A.
    Noble, D. J.
    James, A.
    Lamb, C.
    Grose, D.
    Vohra, S.
    Schipani, S.
    Mactier, K.
    Mackenzie, J.
    Srinivasan, D.
    Laws, K.
    Moleron, R.
    Niblock, P.
    Soh, F. -Y.
    Paterson, C.
    Wilson, C.
    CLINICAL ONCOLOGY, 2024, 36 (05) : 287 - 299
  • [5] Combined chemotherapy and radiation therapy in head and neck cancer
    Nishiyama, K
    Takahashi, H
    Okamoto, M
    Yao, KZ
    Inagi, K
    Nakayama, M
    Makoshi, T
    ACTA OTO-LARYNGOLOGICA, 1996, : 79 - 82
  • [6] Expanding the role of combined immunochemotherapy and immunoradiotherapy in the management of head and neck cancer (Review)
    Wei, Chun
    Lan, Xiaojun
    Qiu, Maona
    Cui, Ran
    Fu, Qiuxia
    Shinge, Shafiu A. Umar
    Muluh, Tobias Achu
    Jiang, Ou
    ONCOLOGY LETTERS, 2023, 26 (03)
  • [7] First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048
    Takahashi, Shunji
    Oridate, Nobuhiko
    Tanaka, Kaoru
    Shimizu, Yasushi
    Fujimoto, Yasushi
    Matsumoto, Koji
    Yokota, Tomoya
    Yamazaki, Tomoko
    Takahashi, Masanobu
    Ueda, Tsutomu
    Hanai, Nobuhiro
    Yamaguchi, Hironori
    Hara, Hiroki
    Yoshizaki, Tomokazu
    Yasumatsu, Ryuji
    Nakayama, Masahiro
    Shiga, Kiyoto
    Fujii, Takashi
    Mitsugi, Kenji
    Takahashi, Kenichi
    Nohata, Nijiro
    Gumuscu, Burak
    Swaby, Ramona F.
    Tahara, Makato
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (12) : 1805 - 1817
  • [8] Alum-anchored IL-12 combined with cytotoxic chemotherapy and immune checkpoint blockade enhanced antitumor immune responses in head and neck cancer models
    Fabian, Kellsye P.
    Santiago-Sanchez, Ginette
    Padget, Michelle R.
    Lassoued, Wiem
    Allen, Clint Tanner
    Battula, Sailaja
    Kaufman, Howard
    Hodge, James W.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (10)
  • [9] Safety outcomes of pembrolizumab with platinum agent chemotherapy combined with 5-fluorouracil or taxane derivative in head and neck cancer
    Lee, Benjamin
    Chehab, Sarah S.
    Fan, Wenyi
    Schell, Michael J.
    Kirtane, Kedar S.
    Shah, Anand B.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2024, 30 (08) : 1397 - 1402
  • [10] Palliative chemotherapy in head and neck cancer: balancing between beneficial and adverse effects
    Rajendra, Akhil
    Noronha, Vanita
    Joshi, Amit
    Patil, Vijay Maruti
    Menon, Nandini
    Prabhash, Kumar
    EXPERT REVIEW OF ANTICANCER THERAPY, 2020, 20 (01) : 17 - 29
12345